Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback